Cellular Biomedicine Raises $14.5M for CAR-T Immunotherapy, Stem Cells

December 29, 2017 -- Cellular Biomedicine Group, a China-US biopharma, added $14.5 million into its treasury through two private placements, one to key executives and the other to outside investors. CBMG is developing a CAR-T immunotherapy for cancer indications and an off-the-shelf stem cell treatment for knee arthritis.  Before the transaction, CBMG had $16 million of cash. The company plans to use the funds for clinical trials and drug development. More

Back to news